Study to Evaluate Blood & Urine Kidney Injury Markers to Facilitate Early

See also
	Status	Clinical Trial	Phase
	Completed	`NCT06160622` - Pharmacokinetics of Leritrelvir(RAY1216) in Participants With Severe Kidney Disease	Phase 1
	Recruiting	`NCT06248567` - Pharmacokinetics of ZSP1273 in Participants With Severe Kidney Disease	Phase 1

See also

Status

Clinical Trial

Phase

Completed

NCT06160622 - Pharmacokinetics of Leritrelvir(RAY1216) in Participants With Severe Kidney Disease

Phase 1

Recruiting

NCT06248567 - Pharmacokinetics of ZSP1273 in Participants With Severe Kidney Disease

Phase 1

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT04308642
Study type	Observational
Source	University Hospital, Basel, Switzerland
Contact	Marc Pfister, Prof MD
Phone	0041 61 704 1851
Email	Marc.Pfister@ukbb.ch
Status	Recruiting
Phase
Start date	October 22, 2020
Completion date	August 2022

Study to Evaluate Blood and Urine Kidney Injury Markers to Facilitate Early Detection of Renal Adverse Drug Events in Pediatric Cancer Patients Treated With Nephrotoxic Chemotherapy — Kid-MaCareOnco

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms